Tesamorelin has an approved indication — what that changes about the evidence — setting out what I have, and where I think it stops being reliable.
What changes if the standard account of tesamorelin is wrong? I ask because I have been treating it as settled and I noticed this week that I could not say why.
Working through the consequences rather than the evidence, since others here are better placed on the evidence.
That matches what I have seen, for whatever a single anecdote is worth.
The most useful single question to ask about any compound in this family is what the published human evidence actually consists of. In several cases the honest answer is a handful of small studies.
I have kept the units in throughout, for the obvious reason.
Post #4 describes the usual case. This is about the unusual one.
Tesamorelin: I would want to see the raw numbers rather than the summary before agreeing. Summaries lose exactly the information that would settle this.
On analysis: these are short peptides and generally straightforward chromatographically, which means a poor purity result is more likely to reflect the synthesis than the method.
Not disagreeing with anyone above, just adding the bit I keep having to look up.
Injection-site reactions are reported more often in this family than for the incretins. Whether that is the compounds or the preparations they are typically supplied in is not established.
Reading rather than contributing, but this is the most useful thread I have found on it.
I had written a reply contradicting post #11 and deleted it. Here is what survived.
A mass result for a short peptide is more discriminating than for a long one, because a single residue difference is a larger proportion of the total. That makes identity confirmation genuinely useful here.
Picking up post #12: that is the part I would want checked first.
Evidence quality in the secretagogue literature is honestly weaker than in the incretin literature. Large randomised controlled trials are rare. Most evidence is mechanistic or from small studies. This is why this subcategory has higher sourcing standards than most.
A modest claim, modestly supported.
Research-use-only secretagogues are not approved for human use. That statement is doing real work in this subcategory, where the published evidence base is thinner than the volume of confident discussion.
If that reads as pedantic, it is, and it has saved me twice.
Tesamorelin has an approved indication in HIV-associated lipodystrophy. That is the only compound in this class with a registration-quality evidence base from a proper trial programme. Generalising from that narrow population to healthy adults is a substantial extrapolation.
That is a description of practice, not a recommendation of it.
Appreciated. The plain phrasing does more work here than a longer post would.
Post #14 describes the usual case. This is about the unusual one.
Effects reported at the level of appetite are the most consistently described and the most mechanistically direct for the ghrelin-receptor compounds, which is not what most people are taking them for.
Worth one more sentence than it usually gets.
Speaking only to tesamorelin as I have actually seen it, rather than as it is usually described: the effect is real, it is smaller than the thread suggests, and the variance between people is larger than the effect.
Reading a rodent study on a secretagogue without over-extrapolating: rodent studies can show a mechanism is plausible. They cannot show magnitude of effect in humans or safety profile in humans. That gap is larger for secretagogues than for incretin agonists because the human evidence is thinner.
If it helps: the failure mode here is usually boring rather than dramatic.
Everything in post #19 holds. The case it does not cover is the one I have.
Where the tesamorelin reasoning breaks down for me is the step from the group result to the individual case. That step is almost never argued for.
Reconstitution volumes in this family are often small enough that dead volume in the syringe is a meaningful fraction of the dose. A fixed-needle insulin syringe is worth the trouble here specifically.
I have said this before in a thread nobody could find, so it is worth repeating.
I read post #23 twice before replying, because I had assumed the opposite.
What I would tell a new member reading about tesamorelin for the first time: the confident posts are not the reliable ones, and the reliable ones are longer.
Post #23 answers the question as asked. The question underneath it is different.
Storage: these are lyophilised short peptides and are generally reasonably stable dry and considerably less so in solution. Reconstituting only what will be used within the period the supplier's own data covers is the conservative approach.
Injection-site reactions are reported more often in this family than for the incretins. Whether that is the compounds or the preparations they are typically supplied in is not established.
The general answer and the answer for your case may diverge here.
Acknowledging rather than arguing. The reasoning holds as far as I can follow it.
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Reading a rodent study on a secretagogue without over-extrapolating
Posting this under the heading it deserves: Reading a rodent study on a secretagogue without over-extrapolating Everything below is what sits behind that. Reading a rodent study, and specifically the version…
|
+50 | 54 | 32k | 10mo |
|
Ipamorelin selectivity claims and where they came from — a second dataset
Posting this under the heading it deserves: Ipamorelin selectivity claims and where they came from — a second dataset Everything below is what sits behind that. Posting a small dataset on Ipamorelin…
|
2 | 27k | 14mo | |
|
Secretagogues and glucose tolerance: the mechanistic concern — what changed since
Secretagogues and glucose tolerance: the mechanistic concern — what changed since Writing it up because I had to work it out twice and would rather nobody else did. What changes if the standard account of…
|
+2 | 6 | 31k | 2mo |
|
GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion
On the subject in the title: GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion Working notes rather than a conclusion. Asking about GHRH analogues versus ghrelin mimetics…
|
+47 | 53 | 6.9k | 2h |
|
IGF-1 as a surrogate endpoint and its limitations — the long version
On the subject in the title: IGF-1 as a surrogate endpoint and its limitations — the long version Working notes rather than a conclusion. A narrow question about IGF-1, deliberately narrow, because the broad…
|
+14 | 18 | 53k | 12mo |
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Publication patterns in the BPC-157 literature, examined
Posting this under the heading it deserves: Publication patterns in the BPC-157 literature, examined Everything below is what sits behind that. Putting the numbers in the first post, because a question about…
|
+40 | 45 | 3.4k | 21h |
|
Whether an aggregate is worth publishing at all: a disputed topic — does this still hold?
Whether an aggregate is worth publishing at all: a disputed topic — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. An honest uncertainty about…
|
+14 | 18 | 3.4k | 2mo |
|
Coming back to: A community side-effect dataset, with its response rate and biases
On the subject in the title: A community side-effect dataset, with its response rate and biases Working notes rather than a conclusion. Reading back through what has been written here about community…
|
+27 | 31 | 46k | 9mo |
|
CJC-1295 with and without DAC: what the modification does
On the subject in the title: CJC-1295 with and without DAC: what the modification does Working notes rather than a conclusion. Putting the numbers in the first post, because a question about a compound…
|
+117 | 123 | 5.6k | 22h |
|
A critique that turned out to be unfair, retracted by its author
Posting this under the heading it deserves: A critique that turned out to be unfair, retracted by its author Everything below is what sits behind that. Critique, and specifically the version of it that the…
|
+34 | 38 | 20k | 17h |